Skip to main content

Advertisement

Table 2 Associations with lytic/latent KSHV# seropositivity

From: Prevalence and predictors of kaposi sarcoma herpes virus seropositivity: a cross-sectional analysis of HIV-infected adults initiating ART in Johannesburg, South Africa

  Overall KSHV#positive Positive to Lytic K8.1 only¥ Positive to Latent Orf 73 onlyβ
  Total Positive
(n, %)
Adjusted PR# (95%CI) Total Positive (n, %) Adjusted PR#
(95%CI)
Total Positive
(n, %)
Adjusted PR# (95%CI)
Gender       
   Female 127 (66%) 1 104 (66%) 1 73 (62%) 1
   Male 66 (34%) 0.96 (0.77-1.19) 54 (34%) 0.98 (0.75-1.26) 44 (38%) 1.16 (0.84-1.60)
Age category       
   < 40 yrs. 118 (61%) 1 94 (59%) 1 69 (60%) 1
   ≥ 40 yrs. 75 (39%) 1.06 (0.86-1.31) 64 (41%) 1.00 (0.78-1.29) 48 (41%) 0.99 (0.73-1.35)
Language       
   Zulu 43 (32%) 1 35 (33%) 1 29 (35%) 1
   Other 90 (68%) 1.21 (0.93-1.58) 71 (67%) 1.17 (0.84-1.62) 54 (65%) 1.09 (0.75-1.59)
Has tuberculosis       
   No 160 (86%) 1 131 (87%) 1 97 (87%) 1
   Yes 25 (14%) 1.06 (0.78-1.42) 20 (13%) 1.08 (0.74-1.57) 15 (13%) 1.06 (0.67-1.67)
BMI category       
   < 18.5 36 (21%) 1 28 (20%) 1 20 (19%) 1
   ≥ 18.5 137 79%) 1.28 (0.97-1.70) 114 (80%) 1.33 (0.94-1.90) 85 (81%) 1.46 (0.94-2.26)
Hemoglobin       
   ≥ 8.5 g/dL 166 (89%) 1 136 (89%) 1 96 (85%) 1
   < 8.5 g/dL 21 (11%) 1.15 (0.84-1.56) 17 (11%) 1.17 (0.80-1.72) 17 (15%) 1.64 (1.11-2.43)
CD4 count       
   0-50 cells 47 (28%) 1 39 (28%) 1 24 (23%) 1
   51-100 cells 39 (23%) 1.18 (0.87-1.62) 29 (21%) 1.03 (0.68-1.55) 28 (27%) 1.61 (0.97-2.66)
   101-200 cells 65 (38%) 1.28 (0.97-1.68) 53 (38%) 1.16 (0.75-1.81) 37 (36%) 1.29 (0.72-2.30)
   201-350 cells 19 (11%) 0.98 (0.65-1.47) 17 (12%) 0.96 (0.52-1.76) 15 (14%) 1.27 (0.59-2.90)
CD3 count       
   < 500 cells 41 (21%) 1 34 (22%) 1 22 (19%) 1
   ≥ 500 cells 152 (79%) 1.35 (1.04-1.76) 124 (78%) 1.31 (0.93-1.84) 95 (81%) 1.62 (1.04-2.54)
CD8 count       
   < 500 cells 64 (33%) 1 54 (34%) 1 35 (30%) 1
   ≥ 500 cells 129 (67%) 1.20 (0.96-1.50) 104 (66%) 1.09 (0.81-1.47) 82 (70%) 1.41 (0.96-2.09)
  1. # KSHV = Kaposi sarcoma herpes virus, PR = prevalence ratio estimated from log-binomial regression model. All models adjusted for sex, age and baseline CD4 count
  2. KSHV negative individuals used as the comparison group
  3. ¥ Those who did not react to lytic K8.1 including the KSHV negative individuals used as the comparison group
  4. β Those who did not react to latent Orf73 including the KSHV negative individuals used as the comparison group